Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Publication year range
1.
Tex Heart Inst J ; 39(3): 351-8, 2012.
Article in English | MEDLINE | ID: mdl-22719143

ABSTRACT

At our institutions, increasing numbers of aortic stenosis patients were not candidates for surgical aortic valve replacement. Accordingly, we initiated the Cali Colombian Transcatheter Aortic Valve Implantation (TAVI) program. From March 2008 through January 2011, 53 consecutive patients (mean age, 79 ± 6 yr; men, 58%) underwent TAVI with the Medtronic CoreValve System, and data were prospectively collected. Our study's endpoints conformed with Valve Academic Research Consortium recommendations. We report our clinical results.Predicted mortality rates were 25% (interquartile range, 17%-34%) according to logistic EuroSCORE and 6% (interquartile range, 3%-8%) according to the Society of Thoracic Surgeons score. The 30-day mortality rate was 9% (3 intraprocedural deaths, 5 total). The combined 30-day safety endpoint was 30% (major vascular sequelae, 23%; life-threatening bleeding, 12%; myocardial infarction, 4%; major stroke, 4%; and acute kidney injury [stage 3], 2%). Eight patients (15%) required post-implantation balloon dilation and 2 (4%) required valve-in-valve implantation, for a technical device success rate of 77%. Mean peak transvalvular gradient decreased from 74 ± 29 to 17 ± 8 mmHg and mean transvalvular gradient from 40 ± 17 to 8 ± 4 mmHg (both P=0.001). Moderate or severe aortic regurgitation decreased from 32% to 18% (P=0.12) and mitral regurgitation from 32% to 13% (P=0.002). The 1-year survival rate was 81%.We found that TAVI with the CoreValve prosthesis was safe and feasible, with sustained long-term results, for treating aortic stenosis in patients at excessive surgical risk; nonetheless, serious adverse events occurred in 30% of the patients.


Subject(s)
Aortic Valve Stenosis/therapy , Cardiac Catheterization/instrumentation , Heart Valve Prosthesis Implantation/instrumentation , Heart Valve Prosthesis , Aged , Aged, 80 and over , Aortic Valve Stenosis/mortality , Cardiac Catheterization/adverse effects , Cardiac Catheterization/mortality , Chi-Square Distribution , Colombia , Female , Heart Valve Prosthesis Implantation/adverse effects , Heart Valve Prosthesis Implantation/methods , Heart Valve Prosthesis Implantation/mortality , Hospital Mortality , Humans , Kaplan-Meier Estimate , Male , Prospective Studies , Prosthesis Design , Risk Assessment , Risk Factors , Time Factors , Treatment Outcome
2.
Rev. colomb. cardiol ; 15(4): 172-183, jul.-ago. 2008. ilus, tab, graf
Article in Spanish | LILACS | ID: lil-532867

ABSTRACT

El ácido acetil salicílico es quizás uno de los medicamentos más antiguos conocidos en el mundo, desde los tiempos de Hipócrates cuando se consumía la corteza del Sauce por sus efectos analgésicos y antipiréticos. Sus propiedades antiplaquetarias fueron reconocidas por primera vez en 1967, y su mecanismo de acción fue dilucidado en 1971. Desde entonces, se usa más por esas propiedades antiplaquetarias que por su efecto analgésico o antipirético.La activación y agregación plaquetaria desempeña un rol importante en la patogénesis de la trombosis arterial, lo cual conduce a síndrome coronario agudo y a complicaciones trombóticas durante y después de intervenciones coronarias percutáneas, de ahí que el ácido acetil salicílico sea el agente antiplaquetario más empleado.Estudios clínicos demuestran su eficacia tanto en prevención primaria como en secundaria de infarto del miocardio, accidente cerebrovascular y muerte cardiovascular. A pesar de sus probados beneficios, el riesgo relativo de eventos vasculares recurrentes entre los pacientes que lo toman permanece relativamente alto, y se estima en 8 porciento a 18 porciento después de dos años. La resistencia terapéutica al ácido acetil salicílico podría explicar en parte este riesgo...


Subject(s)
Aspirin , Blood Platelets , Platelet Aggregation Inhibitors
SELECTION OF CITATIONS
SEARCH DETAIL
...